Determination of Oxaliplatin by a UHPLC-MS/MS Method: Application to Pharmacokinetics and Tongue Tissue Distribution Studies in Rats.
Xiuqing GaoRobert Y L TsaiJing MaYang WangXiaohua LiuDong LiangHuan XiePublished in: Pharmaceuticals (Basel, Switzerland) (2021)
Oxaliplatin (OXP), a third-generation platinum-based chemotherapy drug, was often indirectly analyzed via total platinum by an ICP-MS because it was difficult to directly quantify using an LC-MS/MS method, due to its instability, bad column separability and severe MS signal inhibition. Here, we developed and validated a specific, sensitive and reproducible LC-MS/MS method for the quantification of OXP itself in rat plasma and tongue tissue on a SCIEX 4000 QTRAP ® MS/MS system equipped with a Phenomenex Lux 5u Cellulose-1 column (250 × 4.6 mm, 5 μm). This method was validated at the lower limit of detection (LOD) and the lower limit of quantitation (LLOQ) of 5 ng/mL and 10 ng/mL, with linearity of 10-5000 ng/mL (r 2 > 0.99) and 10-2500 ng/mL (r 2 > 0.99), in rat plasma and tongue homogenates, respectively. The intra- and inter-day precision (CV%) and accuracy (RE%) were within 15% for LLOQ, low-, medium- and high-quality control samples. The mean extraction recoveries were around 50% and 80% for plasma and tongue homogenates, respectively. This assay was successfully applied to pharmacokinetics study following intravenous administration of OXP, as well as tongue tissue distribution after 1 h and 4 h of a novel oral mucosal patch application.
Keyphrases
- ms ms
- solid phase extraction
- liquid chromatography tandem mass spectrometry
- mass spectrometry
- quality control
- liquid chromatography
- high performance liquid chromatography
- simultaneous determination
- multiple sclerosis
- ultra high performance liquid chromatography
- high throughput
- squamous cell carcinoma
- molecularly imprinted
- high resolution
- ionic liquid
- high resolution mass spectrometry
- label free
- electronic health record